OnKure Therapeutics, Inc. filed its quarterly report on Form 10-Q with the SEC on November 4, 2026, covering the fiscal quarter ended September 30, 2026, disclosing a significant increase in cash and a near-tripling of shares outstanding compared to year-end 2025.

Key Highlights

  • Cash position: Cash and cash equivalents stood at $151,443 thousand as of September 30, 2026, up from $59,050 thousand at December 31, 2025.
  • Marketable securities: Available-for-sale marketable securities totaled $11,862 thousand at September 30, 2026, compared to zero at year-end 2025.
  • Total assets: Total assets were $167,077 thousand at September 30, 2026, versus $62,117 thousand at December 31, 2025.
  • Shares outstanding: Class A common stock shares issued and outstanding were 40,503,094 at September 30, 2026, compared to 13,673,565 at December 31, 2025.
  • Total liabilities: Total liabilities were $9,340 thousand at September 30, 2026, up from $5,933 thousand at December 31, 2025.
  • Additional paid-in capital: Additional paid-in capital reached $420,353 thousand at September 30, 2026, compared to $270,424 thousand at December 31, 2025.

OnKure Therapeutics Balance Sheet Details for the Quarter Ended September 30, 2026

According to the filing, OnKure Therapeutics, Inc. (NASDAQ:OKUR), a Delaware-incorporated clinical-stage company headquartered in Boulder, Colorado, reported total current assets of $165,593 thousand as of September 30, 2026, compared to $60,839 thousand at December 31, 2025. The increase was driven primarily by growth in cash and cash equivalents and the addition of available-for-sale marketable securities totaling $11,862 thousand, neither of which were present in material amounts at the prior year-end. Prepaid expenses and other current assets also increased to $2,288 thousand from $1,789 thousand.

On the liabilities side, the company reported total current liabilities of $8,789 thousand, including accounts payable of $2,309 thousand and accrued expenses and other current liabilities of $6,229 thousand. Long-term operating lease liabilities of $539 thousand were also recorded at the quarter's end, compared to zero at December 31, 2025. Total liabilities came to $9,340 thousand, the filing disclosed.

Stockholders' equity reflected a substantial expansion in additional paid-in capital, reaching $420,353 thousand. The accumulated deficit figure in the source text was partially truncated, beginning with "$262,5" before the document ended. The company reported accumulated other comprehensive loss of $(30) thousand at September 30, 2026. As of November 2, 2026, the registrant disclosed 40,503,094 shares of Class A common stock, $0.0001 par value per share, outstanding. The filing also noted that no shares of Class B common stock were issued or outstanding at either balance sheet date. OnKure Therapeutics identified itself as a smaller reporting company and an emerging growth company.

What Was Disclosed

OnKure Therapeutics filed its unaudited condensed consolidated balance sheet data for the quarter ended September 30, 2026, showing material growth in cash, marketable securities, total assets, shares outstanding, and additional paid-in capital relative to December 31, 2025.